Dyslipidemia in pediatric nephrotic syndrome: Causes revisited

Clinical Biochemistry

Volumn 36, Issue 2, 2003, Pages 95-101

  Delvin, Edgard E ^a,b   Merouani, Aicha ^a   Levy, Emile ^b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Cytokines; Lipids; Lipoproteins; MCNS; Nephrotic syndrome

Indexed keywords

LIPID;

CHOLESTEROL SYNTHESIS; CLEARANCE; DYSLIPIDEMIA; HUMAN; HYPERLIPIDEMIA; HYPOALBUMINEMIA; LIPID METABOLISM; NEPHROTIC SYNDROME; NONHUMAN; ONCOTIC PRESSURE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 0037333786     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(02)00433-2     Document Type: Review

References (62)

1. Glassock R.J., Cohen A.H., Adler S.G. Primary glomerular diseases. Brenner B.M. The Kidney. 5th edition:1996;1392-1497 WB Saunders, Philadelphia.
2. Chesney R.W. The idiopathic nephrotic syndrome. Curr opin Pediatr. 11:1999;158-161.
3. North Am Pediatric Renal Transplant Cooperative Study. Ann Report, 1997.
4. RedgraveTG.Chylomicrons. In: Betteridge, Illingworth, Sheperd, editors. Lipoproteins in health and disease. Arnold Publisher, 1999p. 31-54.
5. Hussain M.M. A proposed model for the assembly of chylomicrons. Atherosclerosis. 148:2000;1-15.
6. Davidson M.H. Utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. Am J Cardiology. 87:2001;1A-7A.
7. Williams D.L., Temel R.E., Connelly M.A. Roles of scavenger receptor B1, and apo A-1 in selective uptake of HDL cholesterol by adrenal cells. Endocr Res. 26:2000;639-651.
8. Williams D.L., Connelly M.A., Temel R.E. al. Scavenger receptor B1 and cholesterol trafficking. Curr Opin lipidol. 10:1999;329-339.
9. Attie A.D., Kastelein J.P., Hayden M.R. Pivotal role of ABC1 in reverse cholesterol transport influencing HDL levels, and susceptibility to atherosclerosis. J Lipid Res. 42:2001;1717-1726.
10. Fielding C.J., Fielding P.E. Cellular cholesterol efflux. Biochim Biophys Chim Acta. 1533:2001;175-189.
11. Krause B.R., Auerbach B.J. Reverse cholesterol transport, and future pharmacological approaches to the treatment of atherosclerosis. Curr opin Investig drugs. 2:2001;375-381.
12. Baxter J.H., Goodman H.C., Havel R.J. Serum lipid and lipoprotein alterations in nephrosis. J Clin Invest. 39:1960;455-465.
13. Wanner C., Rader D., Bartens W., et al. Elevated plasma lipoprotein (a) in patients with the nephrotic syndrome. Ann Int Med. 119:1993;263-269.
14. Kaysen G.A. Hyperlipidemia of the nephrotic syndrome. Kidney Int. 39:1991;S8-S15.
15. Wheeler D.C., Bernard D.B. Lipid abnormalities in the nephrotic syndrome Causes, consequences and treatment . Am J Kidney Dis. 23:1994;331-346.
16. Appel G.B., Blum C.B., Chien S., et al. The hyperlipidemia of the nephrotic syndrome: relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med. 312:1985;1544-1548.
17. Kaysen G.A., Gambertoglio J., Felts J., et al. Albumin synthesis, albuminuria and hyperlipidemia of nephrotic patients. Kidney Int. 31:1987;1368-1376.
18. Kaysen G.A., Schoenfeld P.Y. Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int. 25:1984;107-114.
19. Yamauchi A., Fukuhara Y., Yamamoto S., et al. Oncotic pressure regulates gene transcription of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol. 263:1992;C397-C404.
20. Golper T.A., Schwartz S.H. Impaired renal mevalonate metabolism in nephrotic syndrome A stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemia . Metabolism. 31:1982;471-476.
21. Golper T.A., Feingold K.R., Fulford M.H., et al. The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat. J Lipid Res. 27:1986;1044-1051.
22. Chan M.K., Persaud J., Varghese Z., et al. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int. 25:1984;812-818.
23. Roullet J.B., Lacour B., Yvert J.P., et al. Factors of increase in serum triglyceride-rich lipoproteins in uremic rats. Kidney Int. 27:1985;420-425.
24. Olivecrona T., Bengtsson G., Markland S.E., et al. Heparin-lipoprotein lipase interactions. Fed Proc. 36:1977;60-65.
25. Staprans I., Garon S.J., Hooper J., et al. Characterisation of glycosaminoglycans in urine from patients with nephrotic syndrome and control subjects, and their effect on lipoprotein lipase. Biochim Biophys Acta. 678:1981;414-422.
26. Staprans I., Felts J.M., Couser W.G. Glycosaminoglycans and chylomicron metabolism in control and nephrotic rats. Metabolism. 36:1987;496-501.
27. Shearer G.C., Kaysen G.A. Proteinuria, and plasma compositional changes contribute to defective lipoprotein catabolism in the nephrotic syndrome by separate mechanisms. Am J Kidney Dis. 37:2001;S119-S122.
28. Levy E, Ziv E, Bar-On H. Experimental nephrotic syndrome: removal, and tissue distribution of chylomicrons, and very-low-density lipoproteins of normal, and nephrotic origin. Biochim Biophys Acta 1043: 259-66.
29. Moorhead J.F., el Nahas A.M., Harry D., et al. Focal glomerulosclerosis and nephrotic syndrome with partial lecithin:cholesterol acetyl-transferase deficiency and discoidal high density lipoprotein in plasma and urine. Lancet. 1:1983;936-937.
30. Vaziri N.D., Liang K., Parks J.S. Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol. 49:2001;F823-F828.
31. Matsumoto K, Kanmatsuse K. Elevated interleukin-18 levels in the urine of nephrotic patients. Nephron. 88:2001;334-399.
32. Matsumoto K., Kanmatsuse K. Augmented interleukin-18 production by peripheral blood monocytes in patients with minimal-change nephrotic syndrome. Am J Nephrol. 21:2001;20-27.
33. Yap H.K., Cheung W., Murugasu B., et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol. 10:1999;529-537.
34. Neuhaus T.J., Wadwa M., Callard R., et al. Increased IL-2, IL-4 and interferon-gamma(IFN-gamma) in steroid-sensitive nephrotic syndrome. Clin Exp Immunol. 100:1995;475-479.
35. Grunfeld C., Feingold K.R. regulation of lipid metabolism by cytokines during host defence. Nutrition. 12:1996;S24-S26.
36. Feingold K.R., Soued M., Serio M.K., et al. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinol. 267:1989;12574.
37. Feingold K.R., Soued M., Adi S., et al. Effect of interleukin-1 on lipid metabolism in the rat Similarities to and differences from tumour necrosis factor . Arterioscler Thromb. 11:1991;495-500.
38. Hardardottir I, Moser A.H., Memon R., et al. Effect of TNF, IL-1 and the combination of both cytokines on cholesterol metabolism in Syrian Hamsters. Lymphokine Cytokine Res. 13:1994;161-166.
39. Hardardottir I., Sipe J., Moser A.H., et al. LPS and cytokine regulate extra hepatic mRNA levels of apolipoproteins during the acute phase response in Syrian hamsters. Biochem Biophys Acta. 1344:1997;210-220.
40. Khovidhunkit W., Moser A.H., Shigenaga J.K., et al. Regulation of scavenger receptor class B type I in hamster liver, and Hep3B cells by endotoxin, and cytokines. J Lipid Res. 42:2001;1636-1644.
41. Neurath M.F., Becker C., Barbulescu K. Role of Nf-kB in immune and inflammatory responses in the gut. Gut. 43:1998;856-860.
42. Sahali D., Pawlak A., Le Gouvello S., et al. Transcriptional, and posttranscriptional alterations of IkappaBalpha inactive minimal-change nephroticsyndrome. J Am Soc Nephro. 112:2001;1648-1658.
43. Mezzano S.A., Barria M., Droguett M.A., et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int. 60:2001;1366-1377.
44. Gruber P.J., Torres-Rosado A., Wolak M.L., et al. Apo CIII gene transcription is regulated by a cytokine inducible NF-kappa B element. Nucleic Acid Res. 22:1994;2417-2422.
45. Batal R, Tremblay M., Barrett P.H., et al. Plasma kinetics of apoC-III, and apoE in normolipemic, and hypertriglyceridemic subjects. J Lipid Res. 41:2000;706-718.
46. Chan DC, Watts G.F., Barrett P.H., et al. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem. 48:2002;278-283.
47. Kolyada A.Y., Madias N.E. Transcriptional regulationof the human iNOS gene by IL-1beta in endothelial cells. Mol Med. 7:2001;329-343.
48. Hur GM, Ryu Y.S., Hong J.H., et al. Serum after partial hepatectomy stimulates iNOS gene transcription via downstream NF-kappa B site. Biochem Biophys Res Commun. 284:2001;607-613.
49. Trachtman H., Futterweit S., Pine E., et al. Chronic diabetic nephropathy role of inducible nitric oxide synthase . Pediatr Nephrol. 17:2002;20-29.
50. Luoma J.S., Yla-Herttuala S. Expression of inducible nitric oxide synthase in macrophages and smooth muscle cells in various types of human atherosclerotic lesions. Virchows Arch. 434:1999;561-568.
51. Borderie D., Hilliquin P., Hernvann A., et al. Nitric oxide synthase is expressed in the lympho-mononuclear cells of synovial fluid in patients with rheumatoid arthritis. J Rheumatol. 26:1999;2083-2088.
52. Koukouritaki S.B., Tamizuddin A., Lianos E.A. Enhanced expression of the cytoskeletal-associated protein, paxillin, in experimental nephrotic syndrome. J Invest Med. 46:1998;284-289.
53. Strauss J., Zilleruelo G., Freundlich M., et al. Less commonly recognized features of childhood nephrotic syndrome. Pediatr Clin North Am. 34:1987;591-607.
54. Oetliker O., Mordasini R., Lutschg J., et al. Lipoprotein metabolism in nephrotic syndrome in children. Pediatr Res. 14:1980;64-66.
55. Querfeld U., Lang M., Friedrich J.B., et al. Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease. Pediatr Res. 34:1993;772-776.
56. Martin M., Hulley S., Browner W., et al. Serum cholesterol, blood pressure and mortality: Implications from a cohort of 361,662 men. Lancet. II:1986;934-943.
57. Wilson P.W.F., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation. 97:1998;1837-1847.
58. Lamarche B., Tchernof A., Moorjani S., et al. Small, dense low-density lipoprotein particles as predictor of risk of ischemic heart disease in men. Circulation. 95:1997;69-75.
59. Berlyne G., Mallick N. Ischemic heart disease as a complication of nephrotic syndrome. Lancet. II:1969;339-340.
60. Hopper P., Lee J., et al. Lipoid nephrosis in 31 adult patients Renal biopsy study by light, electron and fluorescence microscopy with experience in treatment . Medicine. 49:1970;321-341.
61. Wass VJarrett RChilvers, (1979). Does the nephrotic syndrome increase risk of cardiovascular disease? Lancet. II: 664-7.
62. Hopp L., Gilboa N., Kurland G., et al. Acute myocardial infarction in a young boy with nephrotic syndrome A case report and review of the literature . Pediatr Nephrol. 2:1994;290-294.